- Public Health - Expensive Drugs - Manufacturer Reporting and Drug Price Transparency Advisory Committee
- Sponsored by
- Delegates Bromwell, Anderson, Atterbeary, Barkley, B. Barnes, D. Barnes, Barve, Beidle, Branch, Brooks, Carr, Chang, Clippinger, Conaway, Cullison, Davis, Dumais, Ebersole, Fennell, Fraser-Hidalgo, Frick, Frush, Gaines, Glenn, Gutierrez, Haynes, Healey, Hettleman, Hill, Hixson, Holmes, C. Howard, Jackson, Jameson, Jones, Kaiser, Kelly, Knotts, Korman, Krimm, Lafferty, Lam, Lierman, Lisanti, Luedtke, McCray, McIntosh, A. Miller, Moon, Morales, Oaks, Patterson, Pena-Melnyk, Platt, Proctor, Robinson, Rosenberg, Sample-Hughes, Sanchez, Sophocleus, Stein, Sydnor, Tarlau, Turner, Valderrama, Vallario, Waldstreicher, Walker, A. Washington, M. Washington, C. Wilson, K. Young, P. Young, and R. Lewis
- In the House - Hearing 2/23 at 1:00 p.m.
- Fiscal and Policy Note
Requiring, on or before March 31 each year, the manufacturer of an expensive drug sold or offered for sale in the State to file with the Secretary of Health and Mental Hygiene a specified annual report; establishing the Drug Price Transparency Advisory Committee; requiring a manufacturer of an expensive drug to file a notice with the Secretary before increasing a specified price or a specified cost by more than a specified percentage or amount during specified periods of time; etc.
Bill File Type: Regular
Effective Date(s): October 1, 2017
( 21-228, 21-229, 21-229.1 )
Last Updated: 2/3/2020 2:30 PM